Basic Information
Treovir, LLC Aims to Develop and Commercialize G207, an Oncolytic HSV Virus for Treating Pediatric Brain Tumors. Phase I Clinical Trials Have Been Completed, Proving Safety and Efficacy. In 2021, Treovir Will Launch a Phase II Clinical Study on G207, Aiming to Seek Market Approval for Treating Pediatric Patients with Recurrent Pediatric Glioblastoma.
Treovir, LLC
Philadelphia,Pennsylvania,United States of America
less than 15 people
January 01, 2019
--
--